In this video, Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, shares some insights into the use of CAR-T cell therapy for the treatment of diffuse large B-cell lymphoma (DLBCL) in the second-line setting. Dr Sureda first highlights clinical trials evaluating these agents, and then goes on to discuss the approval of axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel). To conclude, Dr Sureda comments on how the introduction of CAR-T therapy is impacting clinical practice. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.